Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project

Browse Other Projects on Experiment
Related Projects
Y-DNA A00 and the Peoples of Cameroon: In Search of the Homeland
This was the first phase of our fundraising campaign to support our fieldwork in Cameroon. We were very successful...
Dental and Jaw Joint Pathology of the Walrus
Tooth and jaw (temporomandibular) joint (TMJ) diseases are common in certain wildlife species and may be important...